Call 911 or go to the emergency department for fainting or passing out, chest pain or pressure, or trouble breathing. Call your OB or midwife the same day for vaginal bleeding in pregnancy, a fall or a blow to the abdomen, or a change in your baby's movements.
Rh negative means your red blood cells do not carry the D antigen, the surface protein that decides whether a blood type is reported as positive or negative.
The Rh system is a family of proteins embedded in the red cell membrane. Several antigens belong to it, but the one that drives everyday reporting is the D antigen, made from instructions in the RHD gene. People who inherit a working copy of that gene produce the D protein and are reported Rh positive. People who do not produce it are reported Rh negative. Your full blood type pairs the ABO group with the Rh status, so A negative means ABO group A with no D antigen on the cells, and O negative means group O with no D antigen.
Rh status is inherited from both parents. Each parent passes on one copy of the gene region, which is why an Rh-negative parent and an Rh-positive parent can have a child of either Rh type, and why two Rh-positive parents can have an Rh-negative child if both carry a non-functioning copy.
On its own, being Rh negative is an inherited variation in a surface protein. It does not change how oxygen moves around your body or how your immune system handles infection. What it changes is compatibility. Your immune system has never encountered the D antigen, so it can respond to D-positive red cells as foreign if those cells enter your bloodstream, whether through a transfusion or during pregnancy and birth. Rh status also says nothing about personality, intelligence or ancestry beyond ordinary inheritance, despite the claims that circulate online.
Labs determine blood type by mixing a sample of your red cells with reagent antibodies and watching whether the cells clump together.
In forward typing, your red cells are exposed separately to reagent anti-A, anti-B and anti-D. Visible clumping, called agglutination, indicates that the matching antigen is present on your cells. No reaction with anti-D points toward Rh negative. In reverse typing, your plasma is mixed with red cells of known ABO groups to confirm the pattern from the other direction, because people make predictable antibodies against the ABO antigens they lack. The two halves have to agree before the result is reported.
When the reaction with anti-D is absent or weaker than expected, the lab can run additional testing before the report states Rh negative, because some people carry a reduced or altered form of the D protein. In pregnancy, blood typing is paired with an antibody screen, and both results appear on the same report.
Read the result exactly as printed on your lab report, and keep a copy or a photo of it. Your ABO group and Rh type stay the same across your life, although a recent transfusion or a stem cell transplant can make a sample harder to interpret, and the lab or your clinician decides whether repeat testing is needed. If two reports from different labs disagree, that disagreement is worth raising with your OB or midwife rather than resolving yourself.
The antibody screen looks for antibodies in your plasma that react against red cell antigens, including anti-D but not limited to it.
The method is an indirect antiglobulin test, still called an indirect Coombs test in many places. Your plasma is incubated with reagent red cells that carry a known panel of antigens. If antibodies in your plasma attach to those cells, a second reagent makes the reaction visible. A negative screen means no reactive antibodies were detected in that sample. A positive screen sends the sample on for antibody identification, where the lab works out which antigen the antibody targets, and for titer testing, which measures how concentrated it is.
A practice bulletin from the American College of Obstetricians and Gynecologists sets out how alloimmunization is managed during pregnancy, including antibody identification and the role of titers 1. Several antibodies other than anti-D can matter in pregnancy, which is why the screen is broad rather than Rh-specific.
A screen can also react because of preventive care already given during the pregnancy, since the antibody involved can still be circulating when the next sample is drawn. The lab notes this possibility, and your OB or midwife reads the screen alongside your pregnancy history rather than in isolation. A value or result outside what is printed as expected on your report is worth discussing with your clinician, who decides what it reflects and what comes next.
Rh status matters because an Rh-negative pregnant person can make antibodies against an Rh-positive baby's red cells, and those antibodies cross the placenta.
Small numbers of fetal red cells can pass into the pregnant person's circulation. If the baby is RhD positive and the pregnant person is RhD negative, the immune system can recognise the D antigen as foreign and build a lasting antibody response. The antibodies produced are IgG, the class that is actively carried across the placenta, so they can reach the baby's circulation in that pregnancy or in a later one and attach to the baby's red cells.
Research suggests that maternal red cell antibodies crossing the placenta can destroy fetal red cells and lead to fetal anemia and newborn jaundice 2. This is the reason Rh-negative status is flagged early and followed, rather than noted and forgotten.
Fetal cells can cross at birth, and they can also cross at other points in a pregnancy. Situations that can allow mixing include vaginal bleeding, miscarriage, ectopic pregnancy, abdominal injury, invasive procedures such as amniocentesis or chorionic villus sampling, and attempts to turn a baby from the outside. These are listed here without ranking, because the order varies and your OB or midwife assesses your own circumstances. The practical point is simple. If something happens in pregnancy that could cause bleeding or mixing, that is a same-day call to your maternity team, not a wait-and-see.
Rh alloimmunization means a person who is RhD negative has already produced anti-D antibodies after exposure to D-positive red cells.
Once those antibodies exist, they stay in the immune memory, and preventive injections are no longer the approach. Care shifts to monitoring the pregnancy. A 2024 review of management describes antibody identification, repeated titer measurement and ultrasound assessment of the fetus as the framework used when red cell antibodies are present in pregnancy 3. Titers are followed over time because a rising titer changes how closely the pregnancy is watched, and because the threshold for closer surveillance is set by the clinical team, not by the number alone.
When closer surveillance is indicated, fetal anemia can be assessed without entering the uterus, using Doppler ultrasound to measure how fast blood moves through a vessel in the fetal brain. Anemic babies move blood faster because it is thinner. An update on antenatal and postnatal management describes this non-invasive assessment and the escalation pathway that follows it 4.
Alloimmunization can involve antibodies other than anti-D, and the same principle applies. The lab identifies the antibody, the clinical team judges whether it can affect the baby, and the pregnancy is followed accordingly. Care for an alloimmunized pregnancy is led by an obstetric team, sometimes with maternal fetal medicine involvement. Treatment decisions belong to a licensed provider who has reviewed the full picture.
When maternal antibodies attach to fetal red cells, those cells can be broken down faster than the baby can replace them, which is the mechanism behind hemolytic disease of the fetus and newborn.
Before birth, the consequence is anemia. A mildly affected baby can compensate. A more severely affected baby can develop fluid accumulation in body tissues, the condition called hydrops. After birth, the breakdown of red cells releases bilirubin, which the newborn liver has to clear, so jaundice can appear early and rise faster than in an unaffected newborn. A review of alloimmunization and its implications sets out this spectrum from mild anemia through to severe fetal and neonatal disease 2, and a management update describes the newborn monitoring that follows a pregnancy complicated by red cell antibodies 4.
What this means in practice is that an affected pregnancy is watched rather than left to declare itself, and that a newborn born to an alloimmunized parent has blood work done after birth, including the baby's own blood type and a test that looks for antibody already attached to the baby's red cells. The newborn team decides on the level of observation and care required.
None of this is something to work out from your own lab report. A positive antibody screen is a reason to speak with your OB or midwife, who decides what it reflects for your pregnancy and what follow-up is appropriate.
Preventive care works by clearing D-positive fetal red cells from the pregnant person's circulation before the immune system can build a lasting response to them.
The preventive injection contains antibody against the D antigen. Given to someone who is RhD negative and not already immunized, it binds any fetal D-positive cells that have crossed over so they are removed quietly, which stops the immune system from forming its own memory of the antigen. In timing terms, and without putting numbers on it here, preventive care is planned for the later part of pregnancy and again after birth when the newborn is found to be RhD positive. Additional preventive care can be considered after an event that could cause fetal cells to cross, such as bleeding, injury or an invasive procedure.
A systematic review with GRADE analysis of antenatal and postpartum prevention reports that prophylaxis is associated with fewer cases of Rh alloimmunization in RhD-negative pregnancies 5. A separate systematic review examined targeting prophylaxis to pregnancies where the fetus is predicted to be RhD positive, rather than giving it to every RhD-negative pregnant person 6.
The antibody screen comes first for a reason. Preventive injections are intended for people who have not yet formed anti-D, which is why typing and screening are done before any decision is made. Amounts, timing for your own pregnancy and whether preventive care is appropriate are decided by your OB, midwife or another licensed provider, not by a guide like this one.
Some people become immunized even in systems with established prevention, and the reasons are mostly about exposures that were missed rather than about the biology failing.
Research suggests that immunization despite prophylaxis is associated with preventive care that was omitted or given late, and with sensitizing events that were not recognised at the time 7. A bleed that seemed minor, an injury that did not seem worth reporting, or a larger than expected passage of fetal cells at birth can all leave the immune system exposed.
This is the practical reason maternity teams ask Rh-negative patients to report bleeding, falls and abdominal injury the same day rather than at the next scheduled visit. It is also why a test for the volume of fetal cells in the maternal circulation can be run after birth or after a significant event, so the clinical team can judge whether standard preventive care is sufficient in that situation.
For anyone who is Rh negative and planning a pregnancy, the useful actions are ordinary ones. Know your blood type, keep your records so a new clinician does not start from zero, mention any previous pregnancy, miscarriage, ectopic pregnancy or transfusion, and raise anything that caused bleeding. Your clinician decides what preventive steps are appropriate and when.
Yes. Fragments of placental DNA circulate in the pregnant person's blood, and a laboratory can look in that plasma for RHD gene sequences to predict whether the fetus is RhD positive or negative.
The logic is straightforward. An RhD-negative pregnant person does not carry a working RHD gene, so RHD sequences found in their plasma come from the pregnancy. When those sequences are detected, the fetus is predicted RhD positive. When they are absent on an adequate sample, the fetus is predicted RhD negative, and preventive injections would have nothing to protect against.
Studies suggest that antenatal fetal RHD screening using cell-free DNA can separate pregnancies that need preventive care from those that do not, allowing prophylaxis to be targeted 8, and a systematic review examined targeted prophylaxis built on exactly this approach 6. A 2025 review describes fetal Rh(D) screening with cell-free DNA being used when supplies of the preventive product are constrained 9.
There are limits worth knowing. The test depends on enough placental DNA being present in the sample, and gene variants can complicate interpretation, which is why a result can come back inconclusive and why newborn typing after birth remains part of the pathway. Availability differs between health systems. Whether this test is offered in your pregnancy, and how its result is used, is a conversation for your OB or midwife.
Rh typing is unclear for some people because the D antigen is not strictly present or absent. Some people make less of it, and some make a structurally altered version.
Three patterns come up. Weak D describes cells that carry the normal D protein in reduced quantity, so reactions in the lab can be faint. Partial D describes a D protein missing part of its usual structure, so the person can form antibodies against the portion they lack even though they type as positive. DEL describes extremely low expression that routine methods do not detect at all. Different reagents and different methods can therefore place the same person on either side of the positive and negative line.
A systematic review reports that RhD variants among pregnant women can be misclassified when serologic typing is used alone 10. The consequence runs both ways. Someone with a variant can be given preventive care they did not need, or can be recorded as positive and miss care that would have been appropriate.
Genetic testing of the RHD gene can resolve ambiguous serologic results, and some health systems use it routinely for pregnant people whose typing is unclear. If your report carries a comment about weak D, partial D or a variant, that comment is worth raising directly with your OB or midwife, who decides what it reflects for your care and for any future transfusion.
No. Rh status describes a protein on the outside of a red blood cell, while hemoglobin is the oxygen-carrying protein packed inside it, and one does not change the other.
Hemoglobin is still measured in pregnancy as part of a complete blood count, because pregnancy changes blood volume and because anemia from other causes affects how a pregnancy is managed. In pregnancy, read the number as printed on your lab report and review it with your OB or midwife, since the expected values differ from those used outside pregnancy.
For what hemoglobin measures, how the test is performed and how to interpret a result, see the dedicated Hemoglobin guide, which owns that topic in full.
A small group of related tests answers the questions that typing raises.
| Test | What it looks at | Why it can be ordered |
|---|---|---|
| ABO and RhD typing | ABO group and presence of the D antigen on red cells | Establishes blood type for pregnancy care and for any transfusion |
| Antibody screen (indirect antiglobulin test) | Antibodies in plasma that react with red cell antigens | Checks whether alloimmunization has already occurred |
| Antibody identification and titer | Which antigen an antibody targets and how concentrated it is | Guides how closely a pregnancy with antibodies is followed |
| Fetal RHD testing from maternal plasma | Placental DNA fragments carrying RHD sequences | Predicts whether the fetus is RhD positive so preventive care can be targeted |
| Complete blood count | Red cells, white cells, platelets and hemoglobin | Assesses anemia and general blood counts during pregnancy |
| Newborn blood type and direct antiglobulin test | The baby's own type and antibody attached to the baby's red cells | Informs newborn monitoring after an Rh-negative pregnancy |
| Test for fetal cells in maternal blood | Volume of fetal red cells that have crossed over | Helps a clinician judge preventive needs after birth or after an event |
| Hemoglobin electrophoresis | Which hemoglobin types are present | Used when a hemoglobin variant is being considered, separate from Rh status |
FitScript's membership covers 150+ biomarkers tested per year, with results interpreted by Atlas, FitScript's AI health advisor, and any treatment decision made by a licensed provider. Pregnancy blood typing and antibody screening are ordered and read by your OB or midwife as part of maternity care.
Yes, mainly for transfusion. Anyone who is RhD negative can form anti-D if they receive D-positive red cells, so blood banks match Rh status when they can.
In planned transfusion, an RhD-negative recipient is given RhD-negative red cells where supply allows, which avoids creating an antibody that would complicate future transfusions and future pregnancies. In an emergency where there is no time to type the patient, group O RhD-negative red cells can be issued because they are the least likely to react, which is why these units are kept for trauma and why RhD-negative donors are in steady demand.
Knowing your type is also useful before surgery, before a procedure with a bleeding risk, and when registering with a new clinic. It is not something to assume from a parent's blood type or from a childhood memory, because inheritance allows combinations that surprise people and because records are sometimes wrong. A current lab report settles it.
Outside of transfusion and pregnancy, Rh status does not change nutrition needs, training capacity, infection risk or longevity. Claims that link Rh-negative blood to unusual ancestry, special abilities or particular illnesses are not part of how the antigen works. It is a surface protein inherited in an ordinary way.
Blood typing and the antibody screen are done on a standard venous blood draw, and no fasting is required for either test.
The sample goes into a tube so the cells and plasma can be tested separately. Steps in the lab include forward and reverse typing for ABO, testing against anti-D reagent, further testing when the D reaction is weak, and the antibody screen on your plasma. Repeat sampling can be requested if a result is ambiguous or if the previous record disagrees with the new one.
| Line on your report | What it describes | How to read the value |
|---|---|---|
| ABO group | Your A, B, AB or O group | As printed on your lab report |
| Rh (D) type | Whether the D antigen was detected | As printed on your lab report |
| Antibody screen | Whether reactive red cell antibodies were detected | As printed on your lab report |
| Antibody identification and titer | Which antibody was found and its concentration | As printed on your lab report, interpreted by your clinician |
| Weak D or variant comment | A note that D expression was reduced or atypical | As printed on your lab report, raise it with your OB or midwife |
Use the same three steps for any line on the report. The observation is what the lab printed. The meaning is what that result may reflect in your situation, which depends on pregnancy history, transfusion history and the method the lab used. The next step is a conversation. A value or comment outside what the report describes as expected is worth discussing with a clinician, who decides what it reflects.
Any time your report shows something you did not expect, and before any pregnancy decision that depends on Rh status.
Call 911 or go to the emergency department for fainting or passing out, chest pain or pressure, or trouble breathing.
Call your OB or midwife the same day for vaginal bleeding in pregnancy, a fall or a blow to the abdomen, severe abdominal pain, or a change in your baby's movements. These are the situations where the timing of preventive care can matter, and where your maternity team wants to hear from you rather than read about it at the next visit.
Arrange a prompt appointment if your antibody screen is reported positive, if your Rh typing has come back unclear or has changed between labs, if a previous pregnancy involved newborn jaundice requiring hospital care or a transfusion, if you are Rh negative and planning a pregnancy, or if a procedure with a bleeding risk is being scheduled. Bring the printed report with you, including any comment about weak D or variants, because the comment carries information the headline result does not.
This page is educational and is not medical advice. Discuss your own results and any treatment with your clinician or licensed provider, who is the person able to decide what applies to you.
O negative means your red cells carry neither the A nor the B antigen, and they do not carry the RhD protein either. For transfusion, group O RhD-negative red cells are the units blood banks reach for when a patient's type is not yet known. For pregnancy, the negative part is what matters, so the same blood type and antibody screening pathway applies.
Yes. Rh status is inherited from both parents, so an Rh-negative parent and an Rh-positive parent can have a baby of either type. This is the situation the first-visit blood type and antibody screen are designed to pick up early. Your OB or midwife decides what preventive steps are appropriate once your type is known.
Antibodies can form during any pregnancy, including a first one, because fetal red cells can enter the parent's circulation during bleeding, injury, some procedures and at birth. That is why preventive care is planned in advance rather than arranged after a problem appears. Your OB or midwife decides what applies to your pregnancy.
It can, because the baby's Rh type depends on what both parents pass on. Knowing a partner's type gives a clinician extra context, although it does not replace testing. Where available, a blood test on the pregnant person can predict the baby's Rh type directly, and your maternity team decides whether to use it.
It checks whether your plasma contains antibodies that react against red cell antigens, including anti-D and several others that can matter in pregnancy. A negative screen means none were detected in that sample. A positive screen sends the sample on for identification and titer testing, and your clinician decides what it means for your care.
The lab works out which antibody is present and how concentrated it is, and your pregnancy care shifts toward closer monitoring. That can include repeat blood work and ultrasound assessment of the baby, sometimes with a specialist team involved. Bring the printed report to your OB or midwife, who decides what the result reflects and what follow-up is needed.
In some health systems, yes. A sample of the pregnant person's blood can be tested for placental DNA fragments carrying the RHD gene, which predicts whether the baby is Rh positive or negative. A result can come back inconclusive, and the baby's type is confirmed after birth. Ask your OB or midwife whether the test is offered where you are cared for.
Yes. Rh-negative recipients are matched with Rh-negative red cells where supply allows, so that they do not form an antibody that would complicate future transfusions or pregnancies. Rh-negative donors are in steady demand for the same reason. Keep a copy of your blood type report and share it with any new clinic or hospital.